Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring immunogenicity of SARS-CoV-2 vaccination in Dutch middle-aged and older individuals
2021-001976-40Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Circulating IgG antibodies specific for SARS-CoV-2 spike protein after primary vaccination and booster vaccination. Started May 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001976-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001976-40.